Grants and Contributions:
Title:
EB05 COVID-19 Therapy
Agreement Number:
513437
Agreement Value:
$14,054,000.00
Agreement Date:
Apr 23, 2020 - Dec 31, 2022
Description:
Edesa will complete a pre-clinical study, and Phase II trials to evaluate the safety and efficacy of an antibody treatment (EB05) in hospitalized COVID-19 patients.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:
This investment will allow the company to advance their COVID-19 therapeutic candidate (EB05) through Phase II clinical trials, in hopes of advancing to Phase III. This project anticipates the creation of 6 new full-time jobs and will maintain 8 full-time jobs within Canada.
Location:
Markham, Ontario, CA L3R5H6
Reference Number:
033-2020-2021-Q4-513437
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
815678123
Recipient Type:
For-profit organization
Additional Information:
This is a non-repayable contribution.
Recipient's Operating Name:
Edesa Biotech Research, Inc.
Recipient's Legal Name:
Edesa Biotech Research, Inc.
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
SIF Stream 1- R&D
Program Purpose:
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
NAICS Code:
541710